TearClear has raised $34.8m to date to fund an anti-preservative eye drop technology invented at University of Florida.
TearClear, a US-based eye disease therapy developer founded out of University of Florida, has raised $22m of series B funding from investors including venture capital fund Visionary Ventures.
The deal was rounded off by investment partnership Flying L Partners and venture capital and private equity firm Bluestem Capital.
Founded in 2015, TearClear has devised an approach for delivering topical eyedrops while removing preservatives to prevent them from reaching the ocular surface, reducing the likelihood of harmful side-effects such as conjunctival inflammation.
The series B capital will fund work on TearClear’s clinical pipeline including two lead candidates targeting glaucoma.
TearClear has now raised around $34.8m in funding to date, according to regulatory filings.
Visionary Ventures Fund and Bluestem Capital had co-led a $4.5m series A round for the company in 2017 according to VCA Online, with later reports suggesting the sum had reached $5m and represented an initial tranche.
